Crinetics Pharmaceuticals, Inc. (CRNX) CEO Scott Struthers on Q4 2020 Results - Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2020 Earnings Conference Call March 30, 2021 4:30 PM ET

Company Participants

Corey Davis - IR
Scott Struthers - Founder, President, CEO & Director
Alan Krasner - Chief Medical Officer
Marc Wilson - CFO & Secretary

Conference Call Participants

Charles Duncan - Cantor Fitzgerald & Co.
Tyler Van Buren - Piper Sandler & Co.
Joori Park - SVB Leerink
Douglas Tsao - H.C. Wainwright & Co.
Daniel Wolle - JPMorgan Chase & Co.

Operator

Greetings. Welcome to the Crinetics Pharmaceuticals, Inc. 2021 Clinical Strategy and 2020 Financial Results Conference Call. [Operator Instructions].

I will now turn the conference over to your host, Corey Davis. You may begin.

Corey Davis

Thanks, Alex, and thank you all for participating in today's conference call. Before we start, I'd like to point out there is a slide deck that is going to accompany today's presentation. The deck can be viewed using the webcast link provided on the Investor page of the Crinetics website. Also posted on this web page is a news release issued earlier today, announcing Crinetics' 2021 clinical plans and fourth quarter and full year 2020 financial results.

I'd like to remind everyone listening that some of the information contained in the news release and on this call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act and contains forward-looking statements based on current expectations, including statements about the initiation of planned clinical trials. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those stated or implied in such statements due to the risks and uncertainties associated with the company's business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's news release, the company's other news releases, and Crinetics' SEC filings including on its